Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 10;14(9):2005.
doi: 10.3390/v14092005.

Porcine Circovirus Type 2 Vaccines: Commercial Application and Research Advances

Jinshuo Guo  1   2 , Lei Hou  1   2 , Jianwei Zhou  1   2 , Dedong Wang  1   2 , Yongqiu Cui  1   2 , Xufei Feng  1   2 , Jue Liu  1   2
Affiliations
Review

Porcine Circovirus Type 2 Vaccines: Commercial Application and Research Advances

Jinshuo Guo et al. Viruses. .

Abstract

Porcine circovirus type 2 (PCV2) infection can lead to porcine circovirus-associated disease (PCVAD), causing great economic losses to the global swine industry. Conventional vaccination programs are a major measure in the prevention and control of this disease. Currently, there are 5 commercially available PCV2 vaccines in the international market and 10 kinds commercially available PCV2 vaccines in the Chinese market that confer good efficacy against this virus by alleviating clinicopathological manifestations and enhancing growth performance in pigs. In addition, diverse experimental PCV2 vaccines with protective efficiency have been developed, including attenuated chimeric, nucleic acid, subunit, multivalent, and viral-vectored vaccines. These experimental vaccines have been shown to be relatively effective in improving the efficiency of pig production and simplifying prevention procedures. Adjuvants can be used to promote vaccines with higher protective immunity. Herein, we review the application of multiple commercial vaccines over the years and research advances in experimental vaccines, which provide the possibility for the development of superior vaccines to successfully prevent and control PCV2 infection in the future.

Keywords: PCV2; PCVAD; adjuvant; commercial vaccines; experimental vaccines; protective efficiency.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Baekbo P., Kristensen C.S., Larsen L.E. Porcine circovirus diseases: A review of PMWS. Transbound. Emerg. Dis. 2012;59((Suppl. S1)):60–67. doi: 10.1111/j.1865-1682.2011.01288.x. - DOI - PubMed
    1. Correa-Fiz F., Franzo G., Llorens A., Huerta E., Sibila M., Kekarainen T., Segalés J. Porcine circovirus 2 (PCV2) population study in experimentally infected pigs developing PCV2-systemic disease or a subclinical infection. Sci. Rep. 2020;10:17747. doi: 10.1038/s41598-020-74627-3. - DOI - PMC - PubMed
    1. Harding J.C.S. The clinical expression and emergence of porcine circovirus 2. Vet. Microbiol. 2004;98:131–135. doi: 10.1016/j.vetmic.2003.10.013. - DOI - PubMed
    1. Ellis J., Krakowka S., Lairmore M., Haines D., Bratanich A., Clark E., Allan G., Konoby C., Hassard L., Meehan B., et al. Reproduction of lesions of postweaning multisystemic wasting syndrome in gnotobiotic piglets. J. Vet. Diagn. Investig. 1999;11:3–14. doi: 10.1177/104063879901100101. - DOI - PubMed
    1. Segalés J., Rosell C., Domingo M. Pathological findings associated with naturally acquired porcine circovirus type 2 associated disease. Vet. Microbiol. 2004;98:137–149. doi: 10.1016/j.vetmic.2003.10.006. - DOI - PubMed

Publication types

LinkOut - more resources